What is MOTS-c?

A peptide your own cells already make

Every other drug on this site works by binding a receptor somewhere on the outside of a cell. MOTS-c is different. It is encoded inside a short open reading frame in the mitochondrial 12S rRNA gene, the DNA that lives inside your mitochondria rather than in the cell nucleus. Researchers at USC identified it in 2015 and named it a mitochondrial-derived peptide, one of a small family of signals that mitochondria use to talk to the rest of the cell.

That origin matters for how it works. Under metabolic stress, MOTS-c translocates into the nucleus in an AMPK-dependent process and directly influences which genes get switched on. AMPK is the same cellular fuel sensor that exercise and fasting activate, which is the mechanistic reason MOTS-c gets called an exercise mimetic rather than just another metabolic peptide.

What the research actually shows

The strongest data is preclinical. In mice, MOTS-c improves insulin sensitivity, increases glucose uptake in skeletal muscle, and blunts diet- and age-induced obesity. It has also been shown to push fat tissue toward a more thermogenic, calorie-burning state and to protect heart tissue in diabetic mouse models. Separately, MOTS-c levels measured in human blood and muscle rise substantially during a bout of exercise, and levels drop with age. One frequently cited figure: circulating MOTS-c in 70-to-81-year-olds runs about 21% lower than in 18-to-30-year-olds.

None of that is the same as a completed human efficacy trial. Most of the mechanistic case for MOTS-c comes from rodent studies and cell culture, the same category of evidence that underlies a lot of the peptide compounds covered in our peptide stacks guide. The animal data is consistent and comes from multiple independent labs, which is more than some compounds in this category can claim. It still is not proof the effect translates to people at any dose regulators would sign off on.

The one drug candidate built from it

A company called CohBar spent several years developing CB4211, a modified analog of MOTS-c, as a treatment for NASH and obesity. In a Phase 1a/1b trial of 65 healthy volunteers dosed at 25 mg subcutaneously once daily for four weeks, CB4211 was well tolerated with no serious adverse events. The Phase 1b portion, compared against placebo, showed drops in ALT and AST, the standard liver-damage biomarkers, a decrease in glucose, and a trend toward lower body weight.

That trial is the closest thing to real human evidence this molecule has. CohBar shut down and CB4211 was never brought to market. It is also, critically, not the same compound as the unmodified MOTS-c sold by research-chemical vendors online. The dosing, purity, and even the exact sequence differ. Citing CB4211's tolerability as proof that vial-bought MOTS-c is safe is exactly the substitution the FDA's own reviewers flagged when they looked at the evidence file.

What FDA staff found when they looked

MOTS-c is one of seven peptides, alongside BPC-157 and TB-500, nominated for the FDA's 503A Bulk Drug Substances List, the list that would give compounding pharmacies formal authorization to fill a physician-written prescription. On June 30, 2026, FDA career scientists posted their briefing document, and the conclusion was blunt: published literature contains no studies in which compounded MOTS-c or its acetate salt was given to a human, by any route, and no outsourcing facility reported ever compounding it. FDA staff said the evidence does not support the nominated uses, insulin resistance and obesity, and flagged an immunogenicity risk for certain injectable routes on top of the missing efficacy data.

That recommendation sits alongside identical no votes for BPC-157, TB-500, KPV, Semax, Epitalon, and emideltide, which we cover in full in our breakdown of the FDA staff findings. MOTS-c's file was actually one of the thinnest in the group. Peptides like BPC-157 at least had a small, uncontrolled human study to point to. Staff said they found none for MOTS-c at all.

Where the process stands right now

A staff recommendation is not a ruling. The advisory committee, a panel of outside experts, still votes at the July 23-24 hearing, and the FDA makes its own final call after that with no fixed deadline. But a recommendation this stark, zero identified human studies of the actual compounded substance, makes a reversal at the hearing unlikely for MOTS-c specifically. If the FDA follows its own staff, the practical result is that the current situation simply continues: no licensed 503A pathway, and MOTS-c staying in the same unregulated research-chemical market it has always occupied.

Where this leaves the exercise-mimetic idea

The appeal of MOTS-c is easy to understand, especially for anyone dealing with the fatigue and lean-mass loss that can come with rapid weight reduction on a GLP-1, a topic we cover in GLP-1s and muscle loss. A peptide that mimics part of what exercise does to your mitochondria sounds like a shortcut worth taking. The actual evidence right now supports a mechanism, not a proven human benefit. The best-supported way to get the effects MOTS-c is being studied for, better insulin sensitivity, more muscle, more usable energy, is still the exercise it is named after mimicking, paired with adequate protein. MOTS-c may eventually earn a real place in that picture. As of this month, it has not.